![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Vertex licenses TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of its cell therapies, including VX-880, for type 1 diabetes (T1D).
Lead Product(s): VX-880
Therapeutic Area: Endocrinology Product Name: VX-880
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $780.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement April 23, 2024